arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

SAB Biotherapeutics, Inc.

SABS
$2.93 ▼ -0.25 (-7.86%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
24 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Neutral
auto_awesome

Analytical Summary

SAB Biotherapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $233.7M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -8.6% ↘
FCF / Share $-0.14 ↗
Trailing P/E —
Price / Book 1.1x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$114.70K
↓ -62.4% —
Net Income Profit after all expenses
$-18.87M
↓ -263.1% —
Operating Margin Operating profit as % of sales
-420.0%
↓ -15.5% —
FCF / Share Free cash flow per share
$-0.14
↑ +49.7% —

Health Breakdown

Returns
63
Financial Health ↓
10
Cash Quality
4

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 24 quarters